Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy

Progress in Respiratory Research

Volumn 39, Issue , 2010, Pages 95-99

  Kline, Joel N ^a   Krieg, Arthur M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956459668     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000320805     Document Type: Article

References (36)

1. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct Bcell activation. Nature 1995, 374(6522): 546-9.
2. Hayashi T, Beck L, Rossetto C et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004, 114(2): 270-9.
3. Racila DM, Kline JN. Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol 2005, 116(6): 1202-5.
4. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998, 160(6): 2555-9.
5. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999, 104(6): 1258-64.
6. Kitagaki K, Jain VV, Businga TR, Hussain I, Kline JN. Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin Diagn Lab Immunol 2002; 9(6): 1260-9.
7. Jain VV, Kitagaki K, Businga T et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002, 110(6): 867-72.
8. Hussain I, Jain VV, Kitagaki K, Businga TR, OShaughnessy P, Kline JN Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 2002, 112(10): 1819-26.
9. Kline JN, Kitagaki K, Businga TR, Jain VV. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol 2002, 283(1): L170-9.
10. Jain VV, Businga TR, Kitagaki K, George CL, OShaughnessy PT, Kline JN. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol 2003, 285(5): L1137-46.
11. Lee SY, Cho JY, Miller M et al. Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J Allergy Clin Immunol 2006, 117(3): 597-603.
12. Youn CJ, Miller M, Baek KJ et al. Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol 2004, 173(12): 7556-64.
13. Broide DH, Stachnick G, Castaneda D et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 2001, 21(3): 175-82.
14. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999, 162(10): 6284-93.
15. Broide D, Schwarze J, Tighe H et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998, 161(12): 7054-62.
16. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen- conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol 2000, 164(11): 5575-82.
17. Santeliz JV, Nest GV, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002, 109(3): 455-62.
18. Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol 2003, 170(7): 3898-905.
19. Tighe H, Takabayashi K, Schwartz D et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000, 106(1 Pt. 1): 124-34.
20. Mo JH, Park SW, Rhee CS et al. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol 2006, 20(2): 212-8.
21. Ikeda RK, Miller M, Nayar J et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 2003, 171(9): 4860-7.
22. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007, 4(3): 289-94.
23. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007, 117(5): 1184-94.
24. Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22(23-24): 3136-43.
25. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(6): 471-84.
26. Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006, 29(5): 558-68.
27. Appay V, Jandus C, Voelter V et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006, 177(3): 1670-8.
28. Miconnet I, Koenig S, Speiser D et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002, 168(3): 1212-8.
29. Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115(3): 739-46.
30. Pashenkov M, Goes, G, Wagner C et al. Phase II trial of a toll-like receptor 9- activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006, 24(36): 5716-24.
31. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweedtoll- like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355(14): 1445-55.
32. Dynavax presents new analysis of TolambaTM data at ACAAI meeting [news release]. Dynavax Technologies; November 12, 2007. http://investors. dynavax.com/releasedetail.cfm?ReleaseID=275271
33. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, OByrne .M. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006, 174(1): 15-20.
34. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999, 1489(1): 69-84.
35. Henry SP, Beattie G, Yeh G et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2002, 2(12): 1657-66.
36. Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci 1998, 46(2): 365-75.